Merck Taps Nuevolution to Help Identify Drug Targets | GenomeWeb
NEW YORK (GenomeWeb News) – Nuevolution said today that it will use its DNA labeling platform to identify small-molecule leads against drug targets in a collaboration with Merck.
 
Copenhagen-based Nuevolution said it will use its Chemetics platform to screen multi-million member libraries for hit identification, and to perform hit-to-lead optimization.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.